{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:38:35Z","timestamp":1792517915866,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022692","name":"Selfridges Group Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010573","name":"Stichting Dioraphte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>INTRODUCTION<\/jats:title><jats:p>The societal impact of anti\u2010amyloid treatment (AAT) for Alzheimer's disease (AD) depends largely on patient eligibility. Estimates suggest that 1% to 18% of individuals with AD may qualify for AAT; however, data from everyday clinical practice remain limited. This study assessed AAT eligibility in patients at a tertiary memory clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>We included 1309 new patients (63\u00a0\u00b1\u00a08 years, 45% women, Mini\u2010Mental State Examination [MMSE] 25\u00a0\u00b1\u00a05) who presented to the Alzheimer Center Amsterdam (2020\u20132022) for standardized diagnostic workup. Eligibility for AAT was based on lecanemab's approved label guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 1309 new patients, 514 (39% of new patients) had clinical mild cognitive impairment (MCI) or AD. Of these, 108 (8% new patients\/21% clinical MCI\/AD) met Clinical Dementia Rating\/MMSE criteria, were amyloid positive, and had\u00a0&lt;\u00a04 microbleeds\/superficial siderosis. After further excluding apolipoprotein E \u03b54\/\u03b54 homozygotes and anticoagulant users, 79 patients (6% new patients\/15% clinical MCI\/AD) remained eligible.<\/jats:p><\/jats:sec><jats:sec><jats:title>DISCUSSION<\/jats:title><jats:p>Findings indicate limited eligibility for AAT in tertiary memory clinics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Highlights<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Initial eligibility for lecanemab was 8% of all patients and 21% of those with clinical mild cognitive impairment (MCI) or Alzheimer's disease (AD) based on approved guidelines in a tertiary memory clinic population.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>After strict exclusions (such as apolipoprotein E \u03b54\/\u03b54 homozygosity and anticoagulant use), eligibility dropped to 6% of all patients and 15% of those with clinical MCI or AD.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The study highlights the limited real\u2010world applicability of anti\u2010amyloid treatment under current guidelines.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1002\/alz.70375","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:11:29Z","timestamp":1749769889000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["\u201cReal\u2010world\u201d eligibility for anti\u2010amyloid treatment in a tertiary memory clinic setting"],"prefix":"10.1002","volume":"21","author":[{"given":"Sinthujah","family":"Vigneswaran","sequence":"first","affiliation":[{"name":"Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"},{"name":"Alzheimer Center Department of Neurology Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"},{"name":"Amsterdam Neuroscience Program Neurodegeneration Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard G. B.","family":"Vijverberg","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Amsterdam UMC, Vrije Universiteit Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Amsterdam UMC, Vrije Universiteit Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afina W.","family":"Lemstra","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Pijnenburg","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"},{"name":"Amsterdam Neuroscience Program Neurodegeneration Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"},{"name":"Amsterdam Neuroscience Program Neurodegeneration Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[{"name":"Alzheimer Center Department of Neurology Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands"},{"name":"Amsterdam Neuroscience Program Neurodegeneration Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_9_5_1","volume-title":"FDA grants accelerated approval for Alzheimer\u2019s disease treatment lecanemab (Brand Name: LEQEMBI\u2122) [Internet]","author":"Eisai Co., Ltd","year":"2023"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1327"},{"key":"e_1_2_9_7_1","volume-title":"Leqembi Recommended for Treatment of Early Alzheimer's Disease [news release]","author":"European Medicines Agency","year":"2024"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201043"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5789"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17530"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17390"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102019\u2010029663"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.166"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654\u2010025\u201001220\u20101"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_2_9_19_1","volume-title":"Leqembi (Lecanemab\u2011IRMB) Injection for Intravenous Use: Highlights of Prescribing Information","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010132306"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010170850"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004058"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000112852"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.01.001"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c47cc2"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12182"},{"key":"e_1_2_9_30_1","volume-title":"Leqembi recommended for treatment of early Alzheimer\u2019s disease [Internet]","author":"European Medicines Agency","year":"2024"},{"issue":"3","key":"e_1_2_9_31_1","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment","volume":"8","author":"Hlavka JP","year":"2019","journal-title":"Rand Health Q"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00361\u20106"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587\u2010023\u201000404\u20102"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:18:10Z","timestamp":1760008690000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/alz.70375"],"URL":"https:\/\/doi.org\/10.1002\/alz.70375","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70375"}}